First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study

PURPOSE. The aim of this phase III trial was to compare the efficacy and safety of bevacizumab alone with those of bevacizumab and capecitabine plus oxaliplatin (XELOX) as maintenance treatment following induction chemotherapy with XELOX plus bevacizumab in the first-line treatment of patients with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Díaz-Rubio, Eduardo, Gómez-España, Auxiliadora, Massutí, Bartomeu, Sastre, Javier, Abad, Albert, Valladares, Manuel, Rivera, Fernando, Safont, Maria J., Martínez de Prado, Purificación, Gallén, Manuel, González, Encarnación, Marcuello, Eugenio, Benavides, Manuel, Fernández-Martos, Carlos, Losa, Ferrán, Escudero, Pilar, Arrivi, Antonio, Cervantes, Andrés, Dueñas, Rosario, López-Ladrón, Amelia, Lacasta, Adelaida, Llanos, Marta, Tabernero, Jose M., Antón, Antonio, Aranda, Enrique
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2012
Assuntos:
Academia-Pharma Intersect
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3267817/
https://ncbi.nlm.nih.gov/pubmed/22234633
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0249
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados